BR112017003571A2 - terapia combinada - Google Patents

terapia combinada

Info

Publication number
BR112017003571A2
BR112017003571A2 BR112017003571A BR112017003571A BR112017003571A2 BR 112017003571 A2 BR112017003571 A2 BR 112017003571A2 BR 112017003571 A BR112017003571 A BR 112017003571A BR 112017003571 A BR112017003571 A BR 112017003571A BR 112017003571 A2 BR112017003571 A2 BR 112017003571A2
Authority
BR
Brazil
Prior art keywords
combination therapy
effective amount
combination
cognitive
administering
Prior art date
Application number
BR112017003571A
Other languages
English (en)
Inventor
James Mergott Dustin
Cornelious May Patrick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112017003571A2 publication Critical patent/BR112017003571A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Massaging Devices (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção provê um método de tratar uma doença cognitiva ou neurodegenerativa, compreendendo administrar a um paciente em necessidade de tal tratamento uma quantidade eficaz de um composto da fórmula: , ou um sal farmaceuticamente aceitável dos mesmos; em combinação com uma quantidade eficaz de um anticorpo monoclonal anti-n3pglu abeta.
BR112017003571A 2014-09-16 2015-09-08 terapia combinada BR112017003571A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462050967P 2014-09-16 2014-09-16
PCT/US2015/048807 WO2016043997A1 (en) 2014-09-16 2015-09-08 Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor

Publications (1)

Publication Number Publication Date
BR112017003571A2 true BR112017003571A2 (pt) 2017-12-19

Family

ID=54207720

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003571A BR112017003571A2 (pt) 2014-09-16 2015-09-08 terapia combinada

Country Status (27)

Country Link
US (1) US9999624B2 (pt)
EP (1) EP3193882A1 (pt)
JP (1) JP6339741B2 (pt)
KR (1) KR101871128B1 (pt)
CN (1) CN106687136A (pt)
AP (1) AP2017009794A0 (pt)
AR (1) AR101740A1 (pt)
AU (1) AU2015318257B2 (pt)
BR (1) BR112017003571A2 (pt)
CA (1) CA2956835A1 (pt)
CL (1) CL2017000558A1 (pt)
CO (1) CO2017001875A2 (pt)
CR (1) CR20170080A (pt)
DO (1) DOP2017000071A (pt)
EA (1) EA031764B1 (pt)
EC (1) ECSP17015977A (pt)
IL (1) IL250387A0 (pt)
MX (1) MX2017003414A (pt)
NZ (1) NZ728636A (pt)
PE (1) PE20170464A1 (pt)
PH (1) PH12017500493A1 (pt)
SG (1) SG11201701330PA (pt)
SV (1) SV2017005389A (pt)
TN (1) TN2017000072A1 (pt)
TW (1) TWI599358B (pt)
WO (1) WO2016043997A1 (pt)
ZA (1) ZA201700826B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107893A1 (es) * 2016-03-15 2018-06-28 Astrazeneca Ab TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
TWI798751B (zh) * 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JP2019530647A (ja) * 2016-08-18 2019-10-24 イーライ リリー アンド カンパニー Ｂａｃｅ−１阻害剤と抗ｎ３ｐｇｌｕ ａベータ抗体の併用療法
AR110470A1 (es) 2016-10-21 2019-04-03 Lilly Co Eli Terapia de combinación para tratar la enfermedad de alzheimer
CA3041595A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
PT3723807T (pt) 2017-12-14 2021-11-26 H Lundbeck As Tratamentos de associação que compreendem a administração de 1h-pirazolo[4,3-b]piridinas
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
US10350226B1 (en) 2018-06-27 2019-07-16 Joshua O. Atiba Therapy and prevention of prion protein complex infections
WO2021216372A1 (en) * 2020-04-23 2021-10-28 Eli Lilly And Company Subcutaneous absorption and bioavailability of antibodies
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
TW202405020A (zh) 2022-07-29 2024-02-01 美商阿列克特有限責任公司 轉鐵蛋白受體抗原結合域及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060058104A (ko) 2003-08-08 2006-05-29 쉐링 코포레이션 벤즈아미드 치환체를 갖는 사이클릭 아민 ｂａｃｅ-1억제제
TWI423970B (zh) * 2008-01-18 2014-01-21 Eisai R&D Man Co Ltd 經稠合之胺基二氫噻衍生物
DK3042917T3 (en) * 2010-08-12 2018-04-23 Lilly Co Eli ANTI-N3PGLU-AMYLOID-BETA-PEPTIDE ANTIBODIES AND APPLICATIONS THEREOF
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物

Also Published As

Publication number Publication date
CA2956835A1 (en) 2016-03-24
TW201618786A (zh) 2016-06-01
CO2017001875A2 (es) 2017-05-19
PE20170464A1 (es) 2017-04-26
CL2017000558A1 (es) 2017-11-10
CN106687136A (zh) 2017-05-17
TWI599358B (zh) 2017-09-21
CR20170080A (es) 2017-03-30
IL250387A0 (en) 2017-03-30
ECSP17015977A (es) 2018-03-31
MX2017003414A (es) 2017-06-19
US20170224702A1 (en) 2017-08-10
AU2015318257B2 (en) 2018-06-14
TN2017000072A1 (en) 2018-07-04
SV2017005389A (es) 2018-01-17
US9999624B2 (en) 2018-06-19
JP2017529348A (ja) 2017-10-05
KR101871128B1 (ko) 2018-06-25
KR20170036103A (ko) 2017-03-31
ZA201700826B (en) 2018-12-19
AR101740A1 (es) 2017-01-11
EA031764B1 (ru) 2019-02-28
EP3193882A1 (en) 2017-07-26
PH12017500493A1 (en) 2017-08-07
NZ728636A (en) 2018-05-25
AP2017009794A0 (en) 2017-03-31
DOP2017000071A (es) 2017-06-15
SG11201701330PA (en) 2017-04-27
AU2015318257A1 (en) 2017-02-16
EA201790305A1 (ru) 2017-07-31
JP6339741B2 (ja) 2018-06-06
WO2016043997A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
BR112017003571A2 (pt) terapia combinada
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201491857A1 (ru) АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ α7 НИКОТИНОВОГО ХОЛИНОРЕЦЕПТОРА, ИХ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
PH12016502352A1 (en) Pharmaceutical composition
EA201591687A1 (ru) Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
TW201613578A (en) Pharmaceutical combinations
BR112019005539A2 (pt) métodos de tratamento de lesão renal aguda
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201692155A1 (ru) МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
BR112018002763A2 (pt) método para cicatrização de ferimentos
BR112019005217A2 (pt) terapia combinada
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
EA202190626A3 (ru) Комбинация тразодона и габапентина для лечения боли
TR201906539T4 (tr) Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
EA201301340A1 (ru) Фармацевтическая композиция, обладающая нейропротекторным действием, её применение и способы повышения жизнеспособности и профилактики или лечения цереброваскулярных и нейродегенеративных заболеваний

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements